Antipsychotic Medication Trifluoperazine Shows Promise For Fragile X

Trifluoperazine, an approved antipsychotic medication normally prescribed to treat schizophrenia and anxiety, may be a promising therapeutic candidate for people with fragile X syndrome, as suggested by the results of a recently published study. The study, “Transcriptome signature analysis repurposes trifluoperazine for the treatment of fragile X syndrome in mouse model,” was published in Communications Biology. Fragile X, the most frequent genetic cause of autism, is caused by mutations in the FMR1 gene. Despite recent research advances in the molecular mechanisms underlying fragile X, there are no effective medications currently to treat the disorder.

To help identify new therapeutic targets . . .